Management of decreased bone mineral density in men starting androgen‐deprivation therapy for prostate cancer

To determine whether clinicians discuss bone‐specific side‐effects with patients on androgen‐deprivation therapy (ADT) for prostate cancer, or prescribe lifestyle and pharmacological interventions for low bone mineral density (BMD), as decreased BMD is a common side‐effect of ADT, leading to increased risk of fracture.

[1]  B. Clarke,et al.  Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial , 2008 .

[2]  C. Saigal.  Moving beyond guidelines to improve the quality of care for men with prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Alan Bensoussan,et al.  Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis , 2007, The Lancet.

[4]  G. Murata,et al.  Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy , 2007, Journal of General Internal Medicine.

[5]  I. Derweesh,et al.  Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. , 2007, The Canadian journal of urology.

[6]  A. Orsola,et al.  The relationship between daily calcium intake and bone mineral density in men with prostate cancer , 2007, BJU international.

[7]  A. Orsola,et al.  Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. , 2007, Urology.

[8]  S. Gogov,et al.  Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. , 2006, Critical reviews in oncology/hematology.

[9]  M. Carnes,et al.  Androgen Deprivation in Veterans with Prostate Cancer: Implications for Skeletal Health , 2006, The Annals of pharmacotherapy.

[10]  C. Ryan,et al.  Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. , 2006, The Journal of urology.

[11]  P. Warde,et al.  Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. , 2006, Urology.

[12]  G. Duncan,et al.  GU radiation oncologists consensus on bone loss from androgen deprivation. , 2006, The Canadian journal of urology.

[13]  R. Klesges,et al.  A meta-analysis of the effects of cigarette smoking on bone mineral density , 2001, Calcified Tissue International.

[14]  M. Duh,et al.  Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. , 2006, The Journal of urology.

[15]  J. Nelson,et al.  Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  P. Walsh.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The Journal of urology.

[17]  Bess Dawson-Hughes,et al.  Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.

[18]  J. Goodwin,et al.  Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma , 2005, Cancer.

[19]  T. Tanvetyanon.  Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy [An erratum to this Article has been published in Cancer 2006;106(11):2530] , 2005, Cancer.

[20]  Y. Miyaji,et al.  Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. , 2004, Urology.

[21]  C. Higano,et al.  “Osteoporosis in Men with Prostate Carcinoma Receiving Androgen-Deprivation Therapy: Recommendations for Diagnosis and Therapies,” , 2004 .

[22]  J. Eastham,et al.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. , 2003, The Journal of urology.

[23]  D. Lubeck,et al.  Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. , 2002, Urology.

[24]  K. Vincent,et al.  Resistance exercise and bone turnover in elderly men and women. , 2002, Medicine and science in sports and exercise.

[25]  O. Johnell,et al.  Diagnosis of Osteoporosis and Fracture Threshold in Men , 2001, Calcified Tissue International.

[26]  P. Kantoff,et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.